Point72 Asset Management L.P. reduced its position in shares of Calithera Biosciences Inc (NASDAQ:CALA) by 38.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,200,000 shares of the biotechnology company’s stock after selling 735,800 shares during the period. Point72 Asset Management L.P. owned 2.23% of Calithera Biosciences worth $3,708,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of Calithera Biosciences in the second quarter valued at approximately $112,000. Wells Fargo & Company MN boosted its holdings in shares of Calithera Biosciences by 32.6% during the second quarter. Wells Fargo & Company MN now owns 94,890 shares of the biotechnology company’s stock worth $370,000 after purchasing an additional 23,354 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Calithera Biosciences during the second quarter worth $63,000. Monashee Investment Management LLC purchased a new stake in shares of Calithera Biosciences in the second quarter valued at $1,170,000. Finally, Acadian Asset Management LLC grew its position in shares of Calithera Biosciences by 42.2% in the second quarter. Acadian Asset Management LLC now owns 81,239 shares of the biotechnology company’s stock valued at $317,000 after purchasing an additional 24,125 shares during the period. Institutional investors and hedge funds own 65.82% of the company’s stock.
NASDAQ:CALA opened at $4.60 on Tuesday. The company has a quick ratio of 7.39, a current ratio of 7.39 and a debt-to-equity ratio of 0.06. The company has a market cap of $264.57 million, a P/E ratio of -3.09 and a beta of 2.02. Calithera Biosciences Inc has a fifty-two week low of $2.45 and a fifty-two week high of $6.90. The firm’s 50 day moving average is $3.42 and its two-hundred day moving average is $4.04.
Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.07. Research analysts forecast that Calithera Biosciences Inc will post -1.92 earnings per share for the current fiscal year.
CALA has been the topic of several recent analyst reports. ValuEngine downgraded Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, November 19th. HC Wainwright assumed coverage on Calithera Biosciences in a report on Wednesday, November 27th. They issued a “buy” rating and a $7.00 price target for the company. Zacks Investment Research upgraded Calithera Biosciences from a “sell” rating to a “hold” rating in a report on Monday, November 18th. Finally, Citigroup set a $8.00 price objective on shares of Calithera Biosciences and gave the company a “hold” rating in a research note on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Calithera Biosciences presently has a consensus rating of “Hold” and a consensus price target of $6.50.
In other Calithera Biosciences news, major shareholder Bvf Partners L. P/Il acquired 191,954 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was bought at an average cost of $3.91 per share, for a total transaction of $750,540.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bvf Partners L. P/Il acquired 1,598,977 shares of the company’s stock in a transaction dated Tuesday, October 29th. The stock was acquired at an average cost of $2.60 per share, with a total value of $4,157,340.20. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 4,404,157 shares of company stock worth $13,700,668. Company insiders own 17.20% of the company’s stock.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
Featured Story: Back-End Load
Want to see what other hedge funds are holding CALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calithera Biosciences Inc (NASDAQ:CALA).
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.